Cullinan Therapeutics, Inc. CGEM Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cullinan Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cullinan Therapeutics, Inc.'s accrued expenses?
- Cullinan Therapeutics, Inc. (CGEM) reported accrued expenses of $31.92M in Q1 2026.
- How has Cullinan Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Cullinan Therapeutics, Inc.'s accrued expenses increased by 41.2% year-over-year, from $22.6M to $31.92M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s accrued expenses has grown at a 50.7% compound annual growth rate (CAGR), from $4.64M to $36.12M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.